ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis regulation in doxorubicin-induced cardiotoxicity: multi-mechanism interventions and translational strategies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAnthracycline-induced cardiotoxicity is dose-dependent, yet guidelines provide inconsistent cumulative dose thresholds and few standards for converting doses when multiple agents are used. Moreover, no formal guideline exists to unify these practices and responsibilities. Therefore, we evaluated anthracycline dosing and cardiotoxicity monitoring across Dutch hospitals to identify variability.
methodsA national cross-sectional survey was conducted among hospital pharmacists in the first quarter of 2024 in the Netherlands. Hospitals completed a 16‑item questionnaire assessing cumulative dose thresholds, equivalence factors for converting to doxorubicin‑equivalent doses, cardiac monitoring protocols and circumstances under which thresholds are exceeded.
resultsResponses were received from 43 of 69 hospitals (62%). Reported cumulative dose thresholds varied widely for idarubicin (150-450 mg/m
conclusionOur results reveal substantial heterogeneity in anthracycline dosing and cardiotoxicity monitoring across hospitals. Variability in equivalence factors, particularly for mitoxantrone and idarubicin, may lead to misestimation of cumulative cardiotoxic risk. These findings support the need for standardized approaches to dose conversion and improved adherence to cardiac monitoring recommendations to enhance patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.